<DOC>
	<DOCNO>NCT02563782</DOCNO>
	<brief_summary>To evaluate safety 3 regimen short-term , low-dose systemic IMT rejection prophylaxis prior and/or follow transplant MA09-hRPE cell .</brief_summary>
	<brief_title>Study Evaluate Sub-retinal Transplantation Retinal Pigmented Epithelial Cells Patients With Dry AMD</brief_title>
	<detailed_description>This study Phase 2 , double-masked , randomize , parallel group , sham surgery/placebo control , multi-center trial . Subjects randomize 3:1 ratio either treatment control group respectively . Subjects randomize treatment group receive transplantation 200,000 MA09-hRPE ( human embryonic stem cell derive retinal pigmented epithelial ) cell one eye . Subjects randomized control group sham surgery without transplantation MA09-hRPE cell . The study eye must meet eligibility criterion . If eyes meet eligibility criterion , study eye eye worst Best Corrected Visual Acuity ( BCVA ) score screening . If eyes identical BCVA score , study eye choose Investigator subject . There 3 cohort , different regimen low-dose IMT [ tacrolimus mycophenolate mofetil ( MMF ) ] . Subjects randomized treatment control within cohort , define severity BCVA study eye Screening . Enrollment Cohort 1 2 concurrent . Enrollment Cohort 3 begin Cohort 2 fully enrol .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Geographic atrophy ( GA ) secondary AMD evidence prior active choroidal neovascularization ( CNV ) study eye . BCVA study eye must 4 58 Early Treatment Diabetic Retinopathy Study ( EDTRS ) letter ( 20/800 20/80 ; 0.0250.25 ) Subjects must willing take IMT willing discontinue medication know strong interaction tacrolimus mycophenolate mofetil ( MMF ) Macular atrophy due cause AMD Other sightthreatening ocular disease Current prior history optic neuropathy , retinal dystrophy , retinitis pigmentosa , chorioretinitis , vasoocclusive disease , retinal vascular disease retinal degenerative disease OTHER AMD History uveitis History allergic reaction sulfa drug Solid organ bone marrow transplant recipient History malignancy within previous 5 year ( except BCC ( basal cell carcinoma ) , SCC ( squamous cell carcinoma ) insitu cervical ) History myocardial infarction past 12 month History clinically significant cardiac dysrhythmia History diabetes mellitus , bowel disease , tuberculosis Prior treatment nonexudative AMD Intraocular , refractive cataract surgery last 12 week Prior retinal surgery , vitrectomy , macular laser photocoagulation , external beam radiation therapy , transpupillary thermotherapy , glaucoma filtration surgery corneal surgery ( except cataract surgery ) Receipt gene transfer cell transplant therapy prior clinical trial Participation interventional clinical trial within last 12 week</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>